In this issue:
Rivaroxaban + aspirin in patients with high-risk lower extremity PAD
Time course of LDL cholesterol exposure and CV risk
Mortality in AF patients receiving non-recommended doses of DOACs
Early rhythm control in patients with AF
Lipoprotein(a) lowering by alirocumab: the ODYSSEY study
Immune checkpoint inhibitors increase the risk of CV events in cancer patients
Insufficient evidence to recommend low sodium intake
Risk of MACE with SGLT2 vs DPP-4 inhibitors
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy
Health loss due to poor engagement with cardiac rehab in Australia
Please login below to download this issue (PDF)